Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 24 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

42%

10 trials in Phase 3/4

Results Transparency

80%

16 of 20 completed trials have results

Key Signals

3 recruiting16 with results

Enrollment Performance

Analytics

Phase 2
10(50.0%)
Phase 3
9(45.0%)
Phase 4
1(5.0%)
20Total
Phase 2(10)
Phase 3(9)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT07263490Recruiting

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

Role: collaborator

NCT07461909Recruiting

Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer

Role: collaborator

NCT06307184Recruiting

Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer

Role: collaborator

NCT02587000Phase 2Completed

Adenomyosis and Ulipristal Acetate

Role: collaborator

NCT04524026Phase 2Completed

RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2

Role: collaborator

NCT01715805Phase 3Completed

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Role: collaborator

NCT00839852Phase 2Completed

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

Role: collaborator

NCT01838876Phase 3Completed

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

Role: collaborator

NCT01104792Phase 3Completed

Long-term Study of Cariprazine in Patients With Schizophrenia

Role: collaborator

NCT01059539Phase 3Completed

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

Role: collaborator

NCT00694707Phase 2Completed

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

Role: collaborator

NCT00854100Phase 2Completed

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

Role: collaborator

NCT01104779Phase 3Completed

Safety and Efficacy of Cariprazine in Schizophrenia

Role: collaborator

NCT01104766Phase 3Completed

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Role: collaborator

NCT00852202Phase 2Completed

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

Role: collaborator

NCT01412060Phase 3Completed

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Role: collaborator

NCT01396447Phase 2Completed

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Role: collaborator

NCT01469377Phase 2Completed

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Role: collaborator

NCT01058096Phase 3Completed

Safety and Efficacy of Cariprazine for Mania

Role: collaborator

NCT00488618Phase 2Completed

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

Role: collaborator